BioWorld MedTech

Nov. 16, 2015

Mindray merger a precursor to U.S. stock exchange delisting, return to private status

HONG KONG — One of the biggest Chinese medical device companies is undergoing a $3 billion delisting from the U.S. market as it paves the way to head back to its home market and the possibility of more access to investment. Read More

CT colongraphy is again gaining traction on Hill

Mimedx says market overreacted to FDA's recent HCT/P guidance

Colombia defining technological device evaluation guidelines

M&A activity increases as industry gets personal

AHA, Google Life Sciences enter $50M research collaboration

Products

Thermo Fisher authorizes $1 billion share repurchase

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

BioWorld briefs for July 23, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...